The chart looks hard to beat on this stock over almost any time...

The chart looks hard to beat on this stock over almost any time period particularly from 5 years ago.  Key milestones coming up are whether it gets into the ASX200 in March (or will be June, if not in March) and the FDA PDUFA date of 8 July for Scenesse - which is already approved in Europe and making money.  There is also the threat of topical formulations being released by the company although I do not expect this to happen until after July FDA.

What would be of great benefit given the obvious trading accumulation and accompanying scaremongering is an 8horse -style broker analysis over the last 1 month, 3 months & 6 months to get some idea of broker/bot trading patterns.  There is also shorter activity where I calculate the shorters are well into loss and any blip (ex ASX200 inclusion) could be exacerbated by short covering.

If 8horse is reading the 3 broker analyses would be greatly appreciated.